Fallopian Tube Adenocarcinoma

10 clinical trials · Condition

Record	Firm	Date
FT516 and IL2 With Enoblituzumab for Ovarian Cancer (NCT04630769)	Masonic Cancer Center, University of Minnesota	2021-04-02
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (NCT04498117)	CanariaBio Inc.	2020-08-25
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors (NCT03641287)	University of Washington	2018-12-05
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681)	Boston Scientific Corporation	2018-08-27
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma (NCT03608618)	MaxCyte, Inc.	2018-08-27
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02923739)	M.D. Anderson Cancer Center	2017-05-05
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013)	National Cancer Institute (NCI)	2017-01-30
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707)	Mayo Clinic	2014-02-24
Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma (NCT02217956)	Gustave Roussy, Cancer Campus, Grand Paris	2011-06-01
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (NCT00899093)	Gynecologic Oncology Group	2007-09-01

Track Fallopian Tube Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.